MCID: DRG012
MIFTS: 35

Drug Rash with Eosinophilia and Systemic Symptoms malady

Categories: Skin diseases, Immune diseases, Rare diseases

Aliases & Classifications for Drug Rash with Eosinophilia and Systemic Symptoms

Aliases & Descriptions for Drug Rash with Eosinophilia and Systemic Symptoms:

Name: Drug Rash with Eosinophilia and Systemic Symptoms 56
Drug Reaction Eosinophilic Systemic Syndrome 56
Drug Hypersensitivity Syndrome 69
Dress Syndrome 56

Characteristics:

Orphanet epidemiological data:

56
drug rash with eosinophilia and systemic symptoms
Inheritance: Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Orphanet 56 ORPHA139402
UMLS via Orphanet 70 C1142139

Summaries for Drug Rash with Eosinophilia and Systemic Symptoms

MalaCards based summary : Drug Rash with Eosinophilia and Systemic Symptoms, also known as drug reaction eosinophilic systemic syndrome, is related to hepatitis and myocarditis, and has symptoms including renal insufficiency, nephrotic syndrome and skin rash. The drugs Ethanol and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and testes.

Related Diseases for Drug Rash with Eosinophilia and Systemic Symptoms

Diseases related to Drug Rash with Eosinophilia and Systemic Symptoms via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
id Related Disease Score Top Affiliating Genes
1 hepatitis 10.0
2 myocarditis 10.0
3 limbic encephalitis 9.9
4 syndrome of inappropriate antidiuretic hormone 9.9
5 acute generalized exanthematous pustulosis 9.9
6 acute liver failure 9.9
7 glomerulonephritis 9.9
8 interstitial nephritis 9.9
9 hepatitis a 9.9
10 epilepsy 9.9
11 dermatitis 9.9
12 tuberculosis 9.9
13 pancreatitis 9.9
14 encephalitis 9.9
15 exfoliative dermatitis 9.9

Graphical network of the top 20 diseases related to Drug Rash with Eosinophilia and Systemic Symptoms:



Diseases related to Drug Rash with Eosinophilia and Systemic Symptoms

Symptoms & Phenotypes for Drug Rash with Eosinophilia and Systemic Symptoms

Human phenotypes related to Drug Rash with Eosinophilia and Systemic Symptoms:

56 32 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 56 32 Occasional (29-5%) HP:0000083
2 nephrotic syndrome 56 32 Occasional (29-5%) HP:0000100
3 skin rash 56 32 Very frequent (99-80%) HP:0000988
4 erythroderma 56 32 Very frequent (99-80%) HP:0001019
5 cardiac arrest 56 32 Very frequent (99-80%) HP:0001695
6 weight loss 56 32 Very frequent (99-80%) HP:0001824
7 eosinophilia 56 32 Occasional (29-5%) HP:0001880
8 fever 56 32 Very frequent (99-80%) HP:0001945
9 tubulointerstitial nephritis 56 32 Occasional (29-5%) HP:0001970
10 dyspnea 56 32 Occasional (29-5%) HP:0002094
11 pulmonary infiltrates 56 32 Frequent (79-30%) HP:0002113
12 encephalitis 56 32 Very frequent (99-80%) HP:0002383
13 lymphadenopathy 56 32 Very frequent (99-80%) HP:0002716
14 elevated hepatic transaminases 56 32 Frequent (79-30%) HP:0002910
15 interstitial pneumonitis 56 32 Frequent (79-30%) HP:0006515
16 acute hepatic failure 56 32 Occasional (29-5%) HP:0006554
17 peripheral neuropathy 56 32 Occasional (29-5%) HP:0009830
18 erythema 56 32 Very frequent (99-80%) HP:0010783
19 hepatitis 56 32 Occasional (29-5%) HP:0012115
20 macule 56 32 Very frequent (99-80%) HP:0012733
21 cough 56 32 Occasional (29-5%) HP:0012735
22 myocarditis 56 32 Occasional (29-5%) HP:0012819
23 enanthema 56 32 Occasional (29-5%) HP:0030249
24 immunologic hypersensitivity 56 32 Very frequent (99-80%) HP:0100326
25 thyroiditis 56 32 Very frequent (99-80%) HP:0100646
26 angioedema 56 32 Very frequent (99-80%) HP:0100665
27 lymphocytosis 56 32 Frequent (79-30%) HP:0100827
28 pustule 56 32 Occasional (29-5%) HP:0200039

Drugs & Therapeutics for Drug Rash with Eosinophilia and Systemic Symptoms

Drugs for Drug Rash with Eosinophilia and Systemic Symptoms (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1653)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Norepinephrine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
6
Glyburide Approved Phase 4,Phase 3,Phase 2 10238-21-8 3488
7
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
8
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 122320-73-4 77999
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
10
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
11
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
12
Progesterone Approved, Vet_approved Phase 4,Phase 2 57-83-0 5994
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
15
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
18
Verapamil Approved Phase 4,Phase 2,Phase 1 52-53-9 2520
19
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
20
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
21
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
22
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
23
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
24
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
25
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
26
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1 158966-92-8 5281040
27
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
28
chloroquine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54-05-7 2719
29
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
30
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
31
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
32
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1 85721-33-1 2764
33
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
34
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
35
Cidofovir Approved Phase 4,Phase 1 113852-37-2 60613
36
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
37
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
38
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
39
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 67-20-9 5353830
40
Artesunate Approved Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 6917864 5464098
41
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
42
Ramipril Approved Phase 4,Phase 3,Phase 2,Early Phase 1 87333-19-5 5362129
43
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
44
Spironolactone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1952-01-7, 52-01-7 5833
45
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
46
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 58-93-5 3639
47
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
48
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
49
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
50
Atenolol Approved Phase 4,Phase 2 29122-68-7 2249

Interventional clinical trials:

(show top 50) (show all 6003)
id Name Status NCT ID Phase
1 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4
2 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
3 Fludrocortisone's Test in Salt Sensitivity Unknown status NCT01453959 Phase 4
4 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
5 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
6 Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Unknown status NCT01253928 Phase 4
7 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
8 Efficacy of Allergen Immunotherapy for Allergic Rhinitis in Thais Unknown status NCT01115595 Phase 4
9 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
10 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4
11 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4
12 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4
13 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4
14 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
15 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4
16 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Unknown status NCT01678599 Phase 4
17 Safety of Ertapenem in Beta-lactam Allergic Patients. Unknown status NCT01159379 Phase 4
18 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4
19 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4
20 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4
21 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
22 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4
23 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
24 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
25 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Unknown status NCT01618929 Phase 4
26 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4
27 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4
28 EXPAREL® for Pain After Tonsillectomy Unknown status NCT02444533 Phase 4
29 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4
30 Hypervolemia in ESRD Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
31 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4
32 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4
33 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4
34 Predicting the Clinical Response to Omalizumab With Anti-IgE Ab Response or Syk Expression in Basophils Unknown status NCT02023151 Phase 4
35 Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma Unknown status NCT01404013 Phase 4
36 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Unknown status NCT01597531 Phase 4
37 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4
38 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4
39 Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma Unknown status NCT01584804 Phase 4
40 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4
41 Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections Unknown status NCT01142934 Phase 4
42 Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers Unknown status NCT00311220 Phase 4
43 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Unknown status NCT01500785 Phase 4
44 52 Week Trial of Liraglutide in Type 1 Diabetes Unknown status NCT01787916 Phase 4
45 Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia Unknown status NCT01789294 Phase 4
46 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4
47 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity Unknown status NCT01736202 Phase 4
48 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4
49 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Unknown status NCT00920023 Phase 4
50 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4

Search NIH Clinical Center for Drug Rash with Eosinophilia and Systemic Symptoms

Genetic Tests for Drug Rash with Eosinophilia and Systemic Symptoms

Anatomical Context for Drug Rash with Eosinophilia and Systemic Symptoms

MalaCards organs/tissues related to Drug Rash with Eosinophilia and Systemic Symptoms:

39
Skin, Thyroid, Testes, Liver, T Cells, Thymus

Publications for Drug Rash with Eosinophilia and Systemic Symptoms

Articles related to Drug Rash with Eosinophilia and Systemic Symptoms:

(show top 50) (show all 83)
id Title Authors Year
1
Reactivation of Human Herpes Virus-6 in the Renal Tissue of a Patient with Drug-induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic Symptoms (DIHS/DRESS). ( 27374681 )
2016
2
Reactivation of Skin Lesions After Patch Testing to Investigate Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome. ( 27340118 )
2016
3
Leukapheresis in the management of drug rash with eosinophilia and systemic symptoms syndrome. ( 27017438 )
2016
4
Acute tubular necrosis as a part of vancomycin induced drug rash with eosinophilia and systemic symptoms syndrome with coincident postinfectious glomerulonephritis. ( 27186222 )
2016
5
Cefotaxime-induced drug rash with eosinophilia and systemic symptoms syndrome in a 7-year-old boy. ( 27364942 )
2016
6
Oxcarbazepine-induced drug rash with eosinophilia and systemic symptoms syndrome presenting as exfoliative dermatitis. ( 27651712 )
2016
7
Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. ( 27181555 )
2016
8
Isoniazid-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Presenting as Acute Eosinophilic Myocarditis. ( 25986261 )
2015
9
Drug rash with eosinophilia and systemic symptoms caused by the dietary supplement diindolylmethane. ( 26298826 )
2015
10
DRESS Syndrome: Drug Rash with Eosinophilia and Systemic Symptoms. ( 26591154 )
2015
11
Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. ( 25630796 )
2015
12
Drug Rash with Eosinophilia and Systemic Symptoms to antituberculosis treatment. ( 26895118 )
2015
13
Myocarditis in drug rash with eosinophilia and systemic symptoms. ( 25234569 )
2014
14
A Case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Induced by Telaprevir Associated with HHV-6 Active Infection. ( 25239077 )
2014
15
Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. ( 24635062 )
2014
16
HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. ( 25303297 )
2014
17
Drug rash with eosinophilia and systemic symptoms syndrome induced by chloral hydrate in early childhood. ( 24843805 )
2014
18
Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction. ( 25593801 )
2014
19
Ceftriaxone induced drug rash with eosinophilia and systemic symptoms. ( 25114941 )
2014
20
Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. ( 24450829 )
2014
21
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin. ( 23829691 )
2013
22
Cytokine gene expression profiling to help identify a safe antibiotic in a patient with drug rash with eosinophilia and systemic symptoms. ( 24565631 )
2013
23
Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). ( 23141052 )
2013
24
Case report of drug rash with eosinophilia and systemic symptoms demonstrating human herpesvirus-6 reactivation. ( 24016284 )
2013
25
Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. ( 24133560 )
2013
26
Drug Rash with Eosinophilia and Systemic Symptoms Syndrome Due to Anti-TB Medication. ( 24479051 )
2013
27
A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rufinamide. ( 24021364 )
2013
28
Drug rash with eosinophilia and systemic symptoms syndrome associated with use of phenytoin, divalproex sodium, and phenobarbital. ( 23456403 )
2013
29
Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. ( 23361875 )
2013
30
Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome. ( 23741237 )
2013
31
Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report. ( 22511907 )
2012
32
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). ( 22611746 )
2012
33
Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. ( 23165860 )
2012
34
The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. ( 22525393 )
2012
35
Drug rash with eosinophilia and systemic symptoms (DRESS) probably induced by cefotaxime: a report of two cases. ( 21817121 )
2012
36
A case of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome complicating airway management. ( 22271506 )
2012
37
Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. ( 22901319 )
2012
38
Allopurinol causing drug rash with eosinophilia and systemic symptoms syndrome: a challenging diagnosis. ( 22162933 )
2011
39
Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin. ( 21219413 )
2011
40
Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). ( 21951554 )
2011
41
Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant. ( 21217791 )
2011
42
Case of drug rash with eosinophilia and systemic symptoms induced by zonisamide and reactivation of human herpes virus 7. ( 21998830 )
2011
43
Drug rash with eosinophilia and systemic symptoms: two emergency department cases. ( 22224160 )
2011
44
Photodistribution of rash in phenytoin-induced drug rash with eosinophilia and systemic symptoms. ( 21418282 )
2011
45
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by cidofovir. ( 20846239 )
2011
46
Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine. ( 20546480 )
2010
47
Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. ( 20358026 )
2010
48
Antituberculosis drug-induced drug rash with eosinophilia and systemic symptoms syndrome confirmed by patch testing. ( 21314014 )
2010
49
Penicillin V-induced drug rash with eosinophilia and systemic symptoms. ( 21702250 )
2010
50
Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. ( 20653681 )
2010

Variations for Drug Rash with Eosinophilia and Systemic Symptoms

Expression for Drug Rash with Eosinophilia and Systemic Symptoms

Search GEO for disease gene expression data for Drug Rash with Eosinophilia and Systemic Symptoms.

Pathways for Drug Rash with Eosinophilia and Systemic Symptoms

GO Terms for Drug Rash with Eosinophilia and Systemic Symptoms

Sources for Drug Rash with Eosinophilia and Systemic Symptoms

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....